source
- TRexBio raises $117 million in IPO as Retension secures $45 million Nasdaq debut for hypertension therapyTRexBio completed its initial public offering on Thursday, pricing the shares at a level that generated about $116.7 million in gross proceeds. The funding will support the company’s development of…
- City Therapeutics plans $158 million IPO as Iambic eyes $135 million Nasdaq debutCity Therapeutics, an RNAi startup founded by former Alnylam Pharmaceuticals executives, announced plans for an initial public offering targeting roughly $158 million. The company intends to sell a…